SynthesisClinical rheumatology2026
The mediating effects of plasma proteome on the association between selenium and systemic lupus erythematosus.
Synthesis in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesPrevious studies have indicated that elevated selenium levels curb systemic lupus erythematosus (SLE) risk, whereas the specific mechanisms remain to be elucidated. Thereby, our study is conducted to explore the mediating function of proteome on the association between selenium and SLE.
methodsSummary data for plasma proteins came from six large-scale genome wide association studies (GWASs). The data of selenium were derived from a GWAS meta-analysis involving 9639 individuals, and those with SLE were obtained from SLE meta-GWASs (5206 cases and 9066 controls). Two-sample Mendelian randomization (MR) was performed using inverse-variance weighting (IVW), followed by a series of sensitivity analyses to examine the causal relationship between plasma proteins and SLE. Additionally, a two-step MR (TSMR) analysis was applied to explore the mediating role of plasma proteins in the link between selenium and SLE. Moreover, multivariable MR (MVMR) was utilized to adjust and calculate the mediating effect, revealing the potential mechanisms underlying the impact of selenium on SLE.
resultsIn the MR analysis, we found 24 plasma proteins associated with SLE among 4372 unique plasma proteins. Notably, three plasma proteins exhibited a causal link with selenium. Through mediation analysis, we identified sex hormone-binding globulin (SHBG) mediated the causal effect between selenium and SLE. Specifically, increased selenium levels could lower SLE risk by reducing SHBG levels, with a mediation proportion of 22% (95% CI 13-54%).
conclusionsThis research highlights the key mediating role of plasma proteins in the association between selenium and SLE, which elucidates the targeted protein as SHBG for the relationship. Key Points • The research genetically predicted a causal link between plasma proteins and SLE. • The study revealed that plasma proteins mediate the relationship between selenium and SLE. • The findings offer new perspectives and potential intervention targets for SLE prevention through SHBG.
Indexed as
Identifiers
42322540What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.